Ameriprise Financial Inc. Purchases New Position in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Ameriprise Financial Inc. purchased a new stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 408,058 shares of the company’s stock, valued at approximately $649,000. Ameriprise Financial Inc. owned approximately 0.45% of Caribou Biosciences at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Centric Wealth Management acquired a new position in Caribou Biosciences in the fourth quarter worth $27,000. Russell Investments Group Ltd. boosted its stake in Caribou Biosciences by 859.0% in the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock worth $38,000 after purchasing an additional 21,416 shares in the last quarter. MetLife Investment Management LLC boosted its stake in Caribou Biosciences by 60.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock worth $39,000 after purchasing an additional 9,148 shares in the last quarter. Diametric Capital LP acquired a new position in Caribou Biosciences in the fourth quarter worth $42,000. Finally, US Bancorp DE boosted its stake in Caribou Biosciences by 3,524.2% in the fourth quarter. US Bancorp DE now owns 27,218 shares of the company’s stock worth $43,000 after purchasing an additional 26,467 shares in the last quarter. Institutional investors and hedge funds own 77.51% of the company’s stock.

Caribou Biosciences Price Performance

Shares of Caribou Biosciences stock opened at $1.05 on Wednesday. Caribou Biosciences, Inc. has a 1 year low of $0.66 and a 1 year high of $3.00. The business has a 50-day moving average of $0.88 and a two-hundred day moving average of $1.31. The company has a market capitalization of $97.66 million, a P/E ratio of -0.64 and a beta of 2.36.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). The company had revenue of $2.35 million during the quarter, compared to analysts’ expectations of $1.48 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. On average, equities analysts anticipate that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target (down previously from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.